The Christie Charity
The list below shows The Lymphoma Group's current clinical trials open/due to open for recruitment for Diffuse large B-cell lymphoma patients.
If you would like to know how to access our trials, please see how to contact us.
- REMoDL-A - testing acalabrutinib, in combination with R-CHOP, in people with DLBCL who have not been treated before.
- LOTIS-5 - testing a new treatment called loncastuximab tesirine, combined with rituximab, in people with DLBCL that has not responded (refractory) or has come back (relapsed) after previous treatment
- POLA-R-ICE - testing the combination of standard R-ICE chemotherapy with polatuzumab in people with refractory or relapsed DLBCL
- DTP3 - testing a new medication, DTP3, in people with relapsed or refractory diffuse large B cell lymphoma (DLBCL)
- StepPharma/STP938 - testing STP938 in people with T-cell and B-cell lymphomas that has relapsed or is refractory
- NX-5948-301 - testing NX-5948 in patients with relapsed or refractory B cell lymphoma including DLBCL
- M23-324 - phase 1 trial of ABBV-525 in people with B-cell lymphomas
- BYON4228.001 - a phase 1 trial of BYON4228 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
- ATHENA-1 - a phase 1 study of REGN5837 in people with relapsed or refractory B-cell non-Hodgkin lymphomas
- ALETA-001 - a phase 1 and 2 trial of ALETA-001 in patients with relapsed or refractory non-Hodgkin lymphoma
- PORTAL - a phase II trial of polatuzumab vedotin, obinutuzumab and glofitamab in large B-cell lymphoma
With special thanks to the following:
For further information on each trial, please visit the Find a trial page on Lymphoma Action’s website.